Published • loading... • Updated
They Identify a New Protective Effect Against Abdominal Aorta Aneurysm of a Drug Used for Diabetes and Obesity
Summary by Salud a Diario
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The study shows, for the first time, that dual activation of GLP-1 and GIP receptors, therapeutic targets of the drug tirzepatide, reduces inflammation of the aorta wall and slows the development of abdominal aorta aneurysm in an experimental model. The research, whose results have been published in the international journal Pharmacological Research, one of the leading scientific journals in the field of pharmacological and biomedical research, …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
